The 28th Annual Meeting of the Japanese Breast Cancer Society


Etienne Brain

Institut Curie


Matthew J Ellis

Dr Matthew James Ellis a physician scientist who completed his training at the University of London (PhD) and the University of Cambridge (MB BChir). He is currently the Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine where he coordinates an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians focused on improving our ability to prevent, detect and treat breast cancer. His research has focuses on estrogen receptor positive (ER+) breast cancer. He has championed neoadjuvant endocrine therapy as an alternative to chemotherapy for promoting breast-conserving therapy in postmenopausal women with ER+ HER2- stage 2 and 3 disease (JCO 2001, JCO 2011). He developed the Ki67 proliferation marker-based Preoperative Endocrine Prognostic Index (JNCI 2008, JCO 2017) that is now undergoing a large validation study (the ALTERNATE trial). These clinical studies have provided the context and tumor specimens for seminal investigations into the ER+ breast cancer somatic genome, with insights into clonal heterogeneity (Nature Communications 2015), new tumor suppressor genes specific to ER+ disease and new therapeutic targets (Nature 2012). These include activating mutations in the HER2 gene that have been shown respond to HER2 kinase inhibition in clinical trials (Cancer Discovery 2013, Clinical Cancer Research 2017) and somatic loss of function mutations in NF1, which can be targeted with SERD, MEKi combinations (Cancer Cell 2020). He also is a pioneer for patient-derived xenograft research (PDX) in breast cancer. A PDX study in triple negative breast cancer revealed clonal remodeling during brain metastasis (Nature 2010). PDX analysis also revealed acquired resistance to endocrine therapy is a consequence of ESR1 ligand-binding mutation; ESR1 amplification and most uniquely chromosomal translocation causing fusions between the N terminus of ESR1 and the C-terminus of genes that can confer constitutive transcriptional activity (Cell Reports 2013, 2018). To improve our ability to understand the complex genomic changes he has been working with the Clinical Proteomic Tumor Analysis Consortium at the US National Cancer Institute to develop proteogenomic analysis for breast cancer. This mass spectrometry-based approach recently elucidated the functional consequences of somatic mutations, narrowed candidate nominations for driver genes within large deletions and amplified regions and identified therapeutic targets (Nature 2016, Nature Communications 2017, 2020). Dr Ellis, as received many professional rewards for this work, including the 2019 Susan G. Komen Brinker Award for Clinical Research in Breast Cancer.

Laboratory web page

Matthew J Ellis

Lester and Sue Smith Breast Cencer, Baylor College of Medicine


Rosana Ellis

Mrs. Rosana Ellis is a business entrepreneur with direct experience in international management, marketing & finance; She is currently the C.O.O. of PhDsoft Technology Inc. She has launched and successfully managed businesses in the biotech, technology and start-ups business consulting in several countries. She graduated with a dual degree in Business Administration and International Trade, holds a master’s degree in accounting and an MBA. She is fluent in English, Portuguese, Spanish and German.

Mrs. Ellis has been involved in the breast cancer advocacy world for the past 15 years. She participates in countless fundraisers and awareness events, hosted events, assisted in breast cancer projects, attended symposiums and conferences such as San Antonio Breast Cancer Conference and Metastatic Breast Cancer Houston among other conferences such Advancing Innovative Collaborations on Breast Cancer Research, Stockholm.

She graduated from Project Lead, NBCC (National Breast Cancer Coalition) in 2017.
She is current in the board of “Alamo Breast Cancer Foundation” and supports breast cancer advocate organizations such as Theresa’s Research Foundation and Susan Kommen Foundation.

Rosana Ellis

Alamo Breast Cancer Foundation


Wonshik Han

Dr. Han received his MD and PhD degrees from the Seoul National University (SNU) College of Medicine, Korea. He has started faculty appointment in SNU since 2004. Starting from 2015, he has become a tenured Professor of SNU College of Medicine. In Korea, he is a member of board of directors in Korean Breast Cancer Society, The Korean Cancer Association, and Global Breast Cancer Conference (GBCC). He is an active member of AACR and ASCO. He is an associate editor of Journal of Breast Cancer and editorial board of Breast Cancer. He has been devoted to both breast cancer patient care and research. He has published more than 300 original articles in peer reviewed journals, including Journal of Clinical Oncology, Annals of Surgery, Annals of Oncology, Clinical Cancer Research, JAMA Oncology, Genome Biology, and Nature Communications. His clinical research interest is breast cancer in very young age women, development of nomograms for surgical decision, mammographic density, neoadjuvant hormonal therapy, and breast MRI, etc. He has practiced a variety of oncoplastic surgical skills for breast cancer.

Dr. Han also participated in basic and translational research projects. His current interest is to develop clinical tools using Next Generation Sequencing technology. He is also investigating the fields of single cell sequencing and cell-free DNA detection.

Wonshik Han

Department of Surgery, Seoul National University College of Medicine


Chiun-Sheng Huang, MD, PhD, MPH

Chiun-Sheng Huang is the Chairman and Professor of Department of Surgery at the National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. He is also the director of Breast Care Center at the National Taiwan University Hospital. He is currently the chairman of Taiwan Breast Cancer Consortium (TBCC), an academic research organization focusing on multicenter clinical trials.

Prof. Huang has dedicated his career to the prevention and treatment of breast cancer. His research field includes: ultrasound in breast cancer screening and axillary staging; computer-aided diagnosis and detection of breast ultrasound; single nucleotide polymorphism and circulating tumor DNA as susceptibility and prognostic factor for breast cancer; and development of new regimens and biomarkers using neoadjuvant therapy. He has been the study chair of a nationwide randomized trial of breast cancer screening using ultrasound and mammography for women aged 40–49, and a multi-national randomized trial of active immunotherapy in metastatic breast cancer. He has also sit in Steering Committee in several global trials investigating anti-Her-2 target therapies, anti-PDL1 antibody and CDK4/6 inhibitor for breast cancer in adjuvant and neoadjuvant setting. Prof. Huang has published more than 200 papers in related fields. He has been a member of the St. Gallen International Breast Cancer Consensus Panel since 2017 and Honorary President of the Breast Cancer Society of Taiwan.

Professional interests and specialties
Breast Surgery, Surgical Oncology, Breast Ultrasound, Breast Cancer Screening, Molecular Epidemiology, Clinical trial

Chiun-Sheng Huang

National Taiwan University Hospital and College of Medicine, National Taiwan University


Seema A Khan

Dr. Seema A. Khan is Professor of Surgery in the Feinberg School of Medicine at Northwestern University, and the Bluhm Family Professor of Cancer Research. She is the Co-leader of the Cancer Prevention Program at the Robert H. Lurie Comprehensive Cancer Center. She trained in General Surgery and Surgical Oncology; her practice is now limited to patients with breast cancer and those at high risk for it. Her research is primarily focused on breast cancer prevention and is funded by the NIH (NCI), and by the Breast Cancer Research Foundation. She leads the Northwestern Cancer Prevention Consortium, which is funded by the Division of Cancer Prevention of the NCI and includes 15 institutions around the country. Current studies include an examination of the effects of progesterone antagonists in women with breast cancer, and a study of breast cancer risk biomarkers in benign breast biopsy samples. A major focus of Dr. Khan’s work over the last several years involves the development of transdermal delivery of drugs to the breast, with the goal of reducing side effects of prevention drugs, and introducing new drugs to the prevention armamentarium. In the context of breast cancer therapy, Dr. Khan has chaired trials for the Eastern Cooperative Oncology Group (E2108), investigating the role of local therapy for the primary tumor in women presenting with metastatic breast cancer, and the value of breast MRI and the Oncotype DCIS Score in the management of DCIS patients.

Seema A Khan

Northwestern University


Sung-Bae Kim

Sung-Bae Kim is professor and head of breast cancer center at Asan Medical Center, University of Ulsan, Seoul, Korea.

He attained MD and Ph D from Kyunghee Univerisity Medical School, completed clinical training in internal medicine at Ewha Womans University and undertook a clinical fellowship at Division of Hematology-Oncology at Asan Medical Center. He studied at the Experimental Transplantation and Immunology, National Cancer Institute, USA in 2000 as a postdoctoral fellow. He is a member of steering committees in several international clinical trials. His research interests are tumor immunotherapy, molecular imaging, early drug development, and clinical management of head and neck cancer, esophageal cancer, and breast cancer. He has authored several book chapters and written over 250 articles in oncology peer reviewed journals. He has been the principal investigator on a number of clinical trials. He is an author or co-authors of high impact journals such as Lancet Oncology, Lancet, J Clin Oncology, and N Engl J Med.

Sung-Bae Kim

Asan Medical Center, University of Ulsan College of Medicine


Jeong Eon Lee

2005.3-2007.2 __Ph.D. in Medicine ____Seoul National University College of Medicine
2001.3-2005.2 __Master of Science ____Seoul National University College of Medicine
1990.3-1996.2 __Medical Doctor ______Seoul National University College of Medicine

2004.5-2006.2 __Clinical Instructor
______________ General Surgery, Breast Service, Seoul National University Hospital
1997.3-2001.2 __Resident, General Surgery, Seoul National University Hospital
1996.3-1997.2 __Intern, Seoul National University Hospital

2018.4-present _.Professor
2012.4-2018.3 __Associate Professor
2008.3-2012.3 __Assistant Professor
2006.6-2007.11 _Visiting Scholar, Comprehensive Cancer Center, University of Michigan
2006.3-2008.2 __Clinical Assistant Professor
(All above at Samsung Medical Center, Sungkyunkwan University School of Medicine)

2017.4-present __Chair of Scientific Program Committee, Global Breast Cancer Conference 2018
2017.4-present __Chair of Academic Committee, Korean Breast Cancer Society
2016- present ___Vice Editor, Journal of Breast Cancer

Jeong Eon Lee

Breast Division, Department of Surgery, Samsung Medical Center


Bruce Mann

Bruce Mann trained as a general surgeon in Melbourne and completed Fellowships at Memorial Hospital in New York and NCCH in Tokyo in 1998. He was appointed Director of the Breast Tumour Stream of the Victorian Comprehensive Cancer Centre in 2015. He is Chairman of the Board of Breast Cancer Trials – Australia’s clinical trials organisation. He is also on the Board of the Breast Cancer Network Australia, and works with Cancer Australia, BreastScreen Australia and BreastScreen Victoria. His interests relate to systems for optimal breast cancer care and research to tailor the extent of breast cancer treatment to the individual patient.

Bruce Mann

The Royal Womens Hospital


Aleix Prat

Dr. Aleix Prat is currently the Head of the Medical Oncology Department of Hospital Clínic Barcelona (Spain), Associate Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). He obtained his MD degree in 2003 from the University of Barcelona and completed a medical oncology fellowship in 2008 at Vall d ́Hebron Institute of Oncology (VHIO). In 2008, Dr. Prat became a postdoctoral research associate at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou. In 2012, he returned to Barcelona as the Head of the Translational Genomics Group at VHIO and later, he moved to Hospital Clínic and IDIBAPS (2014).

Dr. Prat is a clinical scientist with a longstanding research interest in the clinical application of laboratory findings in breast cancer, with a particular interest in gene expression and the clinical implications of different intrinsic molecular subtypes of breast cancer and also he designs and leads clinical trials of novel drugs and approaches at SOLTI, a Spanish breast cancer cooperative group. As Scientific Coordinator of the Scientific Board of Solti, he was appointed a member of the Executive Committee of The Breast International Group (BIG) in 2018, an international non-profit organization that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. Since May 2019 I left the scientific coordination to assume the Presidency of the Board of Directors of SOLTI.

During his career, he has received competitive funding from different sources including the Spanish government and various other funding organizations such as the Susan G. Komen Foundation and received the International Prize for Breast Cancer Research (Padova, Italy) for his scientific discoveries regarding the characterization and clinical value of the intrinsic subtypes. The more recent and one of the most valuable ones is the award hold by the Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research (150.000 USD) that will allow me to led the project ”Tailoring systemic treatment of Luminal B breast cancer”.In 2018 he was awarded the "Grup Consolidat AGAUR" credential by the Catalonia Government. He holds two issued patents(WO2018/103834A1 and WO/2018/096191), which certificates a stable scientific career.

Since 2007, he has actively taken part in a total of 140 publications (H-score of 47), with a total of 13.479 citations and 95 communications in international conferences. At his early age he has supervised 3 PhD (plus 4 that are current) and 4 Honours students. As well, Dr. Prat has mentored 10 Fellows (5 Research/Clinical Postdocs, Visiting Fellows).

Aleix Prat

Medical Oncology Department at Hospital Clinic of Barcelona


Hope S. Rugo

Hope S. Rugo, MD, FASCO, is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco (UCSF) in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

_Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the Safety Committee for the multicenter adaptively randomized phase II I-SPY2 trial, and also serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator of several TBCRC trials including a multi-center immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.

In addition to her research, Dr. Rugo is an active clinician, and is committed to education, regularly lecturing locally, nationally, and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Giannini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

Hope S. Rugo

Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center


Puay Hoon Tan

Dr Puay Hoon Tan has active interests in breast, urologic and renal pathology, and was a Volume Editor of the 2012 (4th series) WHO Classification of Tumours of the Breast. She is a Standing Editorial Board Member for the 5th series of the WHO Classification of Tumours, IARC, Lyon, and is also an expert member for the Breast volume in this latest series. She sits on the Editorial Boards of Modern Pathology, Breast Cancer Research, Journal of Clinical Pathology, Pathology, Seminars in Diagnostic Pathology. She is Associate Editor of Histopathology and the Singapore Medical Journal. Apart from a busy service largely focused on subspecialty surgical signouts, she and her collaborators are recipients of several research grants related to translational studies of breast and prostate cancer. She is author of more than 400 publications, and participates regularly in regional and international meetings.

Dr Tan’s research interests in breast pathology centre around the classification of breast fibroepithelial lesions and their molecular pathogenesis, triple negative breast cancers, and ductal carcinoma in situ. In urologic pathology, she is engaged in prostate and renal cancer studies and is a contributor to the 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs.

She is a Past-President of the International Society of Breast Pathology, and was Councillor for Asia of the International Society of Urological Pathology (2009 – 2015). She is the current President of the Asian Breast Diseases Association, and the Convenor of the Assembly of Asia-Pacific International Academies of Pathology.

Puay Hoon Tan

Division of Pathology, Singapore General Hospital


Janice Tsang

Dr. Janice Tsang is a Specialist in Medical Oncology and the immediate past Assistant Dean (Alumni Affairs) at the Li Ka Shing Faculty of Medicine, The University of Hong Kong. Janice is currently the Hon. Clinical Assistant Professor at the Li Ka Shing Faculty of Medicine, The University of Hong Kong. Her research interests lie mainly in Breast Oncology, Geriatric Oncology, Translational Research and Psycho-Oncology. Being the first female academic medical oncologist at The University of Hong Kong, Dr. Tsang was awarded the 2014 Hong Kong Ten Outstanding Young Persons Award, and the 2012 Hong Kong City Lady Award (Professional & Academic Category) as the only medical professional receiving this award for the year. She was also the winner of the Psychosocial Oncology Young Investigator Award at the 16th Hong Kong International Cancer Congress & 6th Annual Meeting of Centre for Cancer Research in 2009 and was bestowed the Faculty Teaching Medal in 2012, and the Outstanding Teaching Award (Team Award) for Medical Humanities in 2013 in recognition of her being one of the pioneers in incorporating Medical Humanities in the formal medical curriculum. She has conducted over 80 clinical trials including local, regional and international multi-centred clinical trials, and has been serving as Chairperson for Data Monitoring Committee, Steering Committee Members for major multi-centred clinical trials, and various International and Regional Advisory Boards. She is a key opinion leader in breast oncology both locally and regionally. She is also the Founding Convenor of the Hong Kong Breast Oncology Group (HKBOG) which is now a member of the “Breast International Group” (BIG), being the third Asian member after Japan and Taiwan. She is also appointed as Chair of the CTRG Audit Committee for the National Cancer Institute in 2017, and a member of the International Society of Geriatric Oncology (SIOG), serving as co-track chair for translational research in SIOG. Dr. Tsang is also the Co-Chair of the Organizing Committee of the 8th Global Chinese Breast Cancer Organizations Alliance Conference 2020.

Dr. Tsang is currently the Member of the Specialty Board of Medical Oncology and used to be the Programme Director for Medical Oncology in the Hong Kong Island at the Hong Kong College of Physicians, a member of the Co-ordinating Committee (CoC) for Medical Oncology at the Hospital Authority, and the Deputy Chairperson for the Institutional Review Board for the Hong Kong West Cluster/ HKU (2012-2016), She was the Director of Cancer Centre at the Queen Mary Hospital (2015-2016). She has various appointments in different professional bodies such as the Honorary Advisor for various cancer self-help groups including the
Hong Kong Christian Cancer Care Association, Hong Kong Caner Fund etc. Furthermore, she serves as a member of the Social Welfare Advisory Committee and the Rehabilitation Advisory Committee at the HKSAR Government. She is also the Founding Vice President of the Hong Kong Women Doctors Association, Immediate Past Warden of the Starr Hall at The University of Hong Kong, the current Vice President of The University of Hong Kong Medical Alumni Association (HKUMAA), the Vice President of the Southern District, Hong Kong Girl Guides Association, and the Vice President of the Hong Kong Women Professionals & Entrepreneurs Association.

Janice Tsang

Hong Kong Breast Oncology Group (HKBOG) / The University of Hong Kong


Naoto T. Ueno

Dr. Ueno is a tenured Professor of Medicine at The University of Texas MD Anderson Cancer Center; his research is in the area of inflammatory breast cancer (IBC)/triple negative breast cancer (TNBC) and the molecular mechanism of metastasis and tumorigenicity in breast cancer. He is best known for his various preclinical development and biomarkers which led to novel clinical trials related to breast cancer. He is the Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic and Section Chief of the Translational Breast Cancer Research at Department of Breast Medical Oncology.

The projects in his laboratory include elucidating the role and the underlying mechanism of several signaling pathways, including epidermal growth factor receptor, transforming growth factor beta (TBF- beta), c-Jun N-terminal kinase (JNK), and Axl receptor tyrosine kinase, in promoting the progression of TNBC and IBC. His research also focuses on determining the impact of the tumor microenvironment on the efficacy of targeted therapy and establishing novel therapeutic approaches by modulating the tumor microenvironment. His significant current extramural funding is R01, R21, CPRIT, and BCRF. He has more than six ongoing investigator-initiated clinical trials for patients with IBC and TNBC.

Outside of MD Anderson and the GSBS, Dr. Ueno has had extensive experience in directly supervising trainees in the Japanese TeamOncology Program and Clinical Skill Advancement Workshop. Currently, he is a mentor for 100 participants in the program. He also directly supervises numerous medical students, graduate students, and clinical residents and fellows other than those at MD Anderson and The University of Texas Graduate School of Biomedical Science. He also serves as a standing member of the Drug Discovery and Molecular Pharmacology Study Sections, NIH. He is the chief-in-editor of Journal of Cancer and serve as the editor of Journal of National Cancer Institute.

Dr. Ueno received the Nylene Eckles Distinguished Professorship of Breast Cancer Research in 2012. Dr. Ueno received The University of Texas System Regents' Outstanding Teaching Award for his mentoring contributions in 2014 and MD Anderson Distinguished Clinical Faculty Mentor Award in 2019.

Naoto T. Ueno

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center

c/o Congrès Inc.

3F Onward Park Building,
3-10-5 Nihonbashi, Chuo-ku,
Tokyo 103-8239, Japan
TEL: +81-3-3510-3701
Fax: +81-3-3510-3702